Pharmacology

Leadership:

Bajin Han, M.D., Ph.D., executive director of pharmacology
Qingyang Gu, Ph.D., associate director of pharmacology
Hong Li, Ph.D., assistant director of pharmacology

Our pharmacology team has extensive drug discovery and development experience in the pharmaceutical industry, giving us the ability to fully support integrated programs including study design and data interpretation. By working closely with our drug metabolism and pharmacokinetics (DMPK) group, we are able to integrate pharmacodynamic and efficacy endpoints with drug distribution.

BioDuro’s pharmacology team currently focuses on metabolic diseases including diabetes and obesity. Future disease areas of interest include other metabolic disorders, inflammation and central nervous system (CNS) diseases. In addition, our broad background in pharmacology has allowed us to successfully establish disease-specific models to support integrated programs not related to metabolic disorders such as osteoporosis and hematopoiesis.

Pharmacology Studies:

Metabolic disorders
- Diabetes
- Obesity
- Dyslipidemia
Inflammation
- LPS-induced cytokine model
- Topical arachidonic acid model
- Inflammatory pain
Integrated efficacy/pharmacodynamic/drug distribution studies
AAALAC-accredited facilities